PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	MERGER
EFFECTIVE DATE:	10/07/1999

CONVEYING PARTY DATA

Name	Execution Date
ImaRx Pharmaceutical Corp.	10/07/1999

RECEIVING PARTY DATA

Name:	DuPont Contrast Imaging Inc.	
Street Address:	1007 Market Street	
City:	Wilmington	
State/Country:	DELAWARE	
Postal Code:	19898	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	11252659

CORRESPONDENCE DATA

Fax Number: (617)646-8646

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

617-646-8000 Phone:

Email: patents_MaryDilysA@wolfgreenfield.com

Correspondent Name: MaryDilys S. Anderson Address Line 1: 600 Atlantic Avenue

Address Line 4: Boston, MASSACHUSETTS 02210

NAME OF SUBMITTER: MaryDilys S. Anderson

Total Attachments: 10

source=N046970029US10-MERGER#page1.tif source=N046970029US10-MERGER#page2.tif source=N046970029US10-MERGER#page3.tif source=N046970029US10-MERGER#page4.tif source=N046970029US10-MERGER#page5.tif

500999588 REEL: 023433 FRAME: 0092

PATENT

source=N046970029US10-MERGER#page6.tif source=N046970029US10-MERGER#page7.tif source=N046970029US10-MERGER#page8.tif source=N046970029US10-MERGER#page9.tif source=N046970029US10-MERGER#page10.tif

State of Delaware

Office of the Secretary of State

I, EDWARD J. FREEL, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREEY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPT OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"IMARK PEARMACEUTICAL CORP.", A ARIZONA CORPORATION,

WITE AND INTO "DUPONE CONTRAST INAGING INC." UNDER THE NAME OF "DUPONE CONTRAST INAGING INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE SEVENTE DAY OF OCTOBER, A.D. 1999, AT 4:30 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE MEM CASTLE COUNTY RECORDER OF DEEDS.

3098309 8100%

991425277

Edward J. Freel, Secretary of State
0016700

AUTHENTICATION:

10-08-99

DATE

CERTIFICATE OF MERGER
OF
IMARX PHARMACEUTICAL CORP.

(an Arizona corporation)
with and into
DUPONT CONTRAST IMAGING INC.
(a Delaware corporation)

Pursuant to Section 252 of the Delaware General Corporation Law

The undersigned corporations DO HEREBY CERTIFY:

FIRST: That the name and state of incorporation of each of the constituent corporations which is to merge is as follows:

Name

Jurisdiction

ImaRx Pharmaceutical Corp. DuPont Contrast Imaging Inc. Arizona Delaware

SECOND: That an Agreement and Plan of Merger has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations in accordance with the provisions of the Section 252 of the Delaware General Corporation Law. Such approval by the shareholders of ImaRx Pharmaceutical Corp. was obtained at a special meeting of the shareholders held on October 7, 1999. No vote of the stockholders of DuPont Contrast Imaging Inc. was necessary to authorize the merger.

THIRD: That the name of the surviving corporation is DuPont Contrast Imaging Inc.

FOURTH:— That the Certificate of Incorporation of DuPont Contrast Imaging Inc., the surviving corporation, as is in effect on the date of the merger provided in the Agreement and Plan of Merger shall continue in full force and effect as the Certificate of Incorporation of the corporation surviving this merger.

FIFTH: That the executed Agreement and Plan of Merger is on file at the principal place of business of DuPont Contrast Imaging Inc., the surviving corporation, at 1007 Market Street, Wilmington, Delaware 19898.

PHE_A 1500104 v 2

SIXTH: That a copy of the Agreement and Plan of Merger will be furnished by DuPont Contrast Imaging Inc., the surviving corporation, on request and without cost, to any stockholder (or shareholder) of any constituent corporation.

SEVENTH: That the manner of converting the shares of the capital stock of the merged corporation into shares or other securities of E.I. du Pont de Nemours and Company, the parent corporation of the surviving corporation, shall be as follows:

- (a) Each share of common stock of the surviving corporation, which shall be issued and outstanding on the effective date of the Agreement and Plan of Merger, shall remain issued and outstanding.
- (b) Each share of common stock of the merged corporation which shall be outstanding on the effective date of the Agreement and Plan of Merger, and all rights in respect thereto, shall forthwith be changed and converted into cash and shares of common stock of E.I. du Pont de Nemours and Company.
- holder of an outstanding certificate representing the shares of common stock of the merged corporation shall surrender the same to E.I. du Pont de Nemours and Company, the parent corporation of the surviving corporation, and each such holder shall be entitled upon such surrender to receive the number of shares of common stock of E.I. du Pont de Nemours and Company on the basis provided therein. Until so surrendered, the outstanding shares of stock of the merged corporation to be converted into the stock of E.I. du Pont de Nemours and Company as provided therein, may be treated by E.I. du Pont de Nemours and Company and the surviving corporation for all corporate purposes as evidencing the ownership of shares of E.I. du Pont de Nemours and Company as though said surrender and exchange had taken place. After the effective date of the Agreement and Plan of Merger, each registered owner of any uncertificated shares of common stock of the merged corporation shall have said shares cancelled and said registered owner shall be entitled to the number of common shares of E.I. du Pont de Nemours and Company on the basis provided therein.

EIGHTH: The authorized capital stock of ImaRx Pharmaceutical Corp. consists of 5,000,000 shares of common stock, par value 5.01 per share.

Z

IN WIFNESS WHEREOF, each of the undersigned has caused this Certificate of Merger to be signed by a duly authorized officer this 110 day of October, 1999.

IMARX PHARMACEUTICAL CORP.

Name: Evan C. Unger

Title: President and Chief Executive Officer

DUPONT CONTRAST IMAGING INC.

By:

Name: Nicholas L. Teti

Title: President

DLE A 1500104 u 2

PATENT

IN WITNESS WHEREOF, each of the undersigned has caused this Certificate of Merger to be signed by a duly authorized officer this 1th day of October, 1999.

IMARX PHARMACEUTICAL CORP.

By:_

Name: Evan C. Unger

Title: President and Chief Executive Officer

Name: Micholas Z. T Title: President

PATENT

DUPONT CONTRAST IMAGING INC.

Secretary's Certificate

I, Robert Pelzer, secretary of DuPont Contrast Imaging Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certify, as such secretary, that the Agreement and Plan of Merger, after having been first duly signed on behalf of said corporation and having been signed on behalf of ImaRx Pharmaceutical Corp., a corporation of the State of Arizona, was duly adopted pursuant to subsection (f) of Section 251 of Title 8 of the Delaware Code without any vote of the stockholders of said corporation, as the surviving corporation; and that the Agreement and Plan of Merger does not amend in any respect the Certificate of Incorporation of said corporation, as the surviving corporation, and each share of stock of said corporation, as the surviving corporation, outstanding immediately prior to the effect of the merger is to be an identical outstanding or treasury share of the surviving corporation after the effective date of the merger; no shares of common stock of said corporation, as the surviving corporation, and no shares, securities or obligations convertible into such stock shall be issued or delivered under the Agreement and Plan of Merger and that the foregoing were such as to render subsection (f) of Section 251 of Title 8 of the Delaware Code applicable; and that the Agreement and Plan of Merger was thereby adopted by action of the Board of Directors of said DuPont Contrast Imaging Inc., and is the duly adopted agreement and act of said corporation.

IN WITNESS WHEREOF, I have executed this Certificate as of the day of October, 1999.

Name: Robert Pelzer, Secretary

BM A (100104 ...

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CHANGE OF NAME IN RECORDED ASSIGNMENTS

1. Particulars of assignments

A list of the patent applications and patents for which the change of name in the recorded assignment is requested is set forth in Schedule A (granted patents) and Schedule B (pending patent applications) attached hereto.

2. Old name of assignee

The old name of the assignee shown on the above-referenced assignments is ImaRx Pharmaceutical Corp.

3. New name and address of assignee

The new name of the assignee is DuPont Contrast Imaging Inc.

4. Proof of change of name

Proof of change of name is established by the attached certificate from the following authority: Office of the Secretary of State - State of Delaware

5. Payment of fee

Please refer to the RECORDATION FORM COVER SHEET, to which this paper is attached.

Blair Q. Ferguson Reg. No. 34,329

Counsel, Intellectual Property
Experimental Station, E353/133C
Route 141 and Henry Clay Road
Wilmington, DE 19880-0353

Phone: 302/695-3902

(Change of Name in Recorded Assignments—page 1 of 1)

Form PTO-1595 RECORDATION FORM (Rev. 03/01) OMS No. 0851-0027 (exp. 5/31/2002) PATENT	11 C Second and Tandament Office	
Tain settings ⇔ ⇔ ♥ ▼	T T T	
To the Honorable Commissioner of Patents and Trademarks:	Messe record the attached original documents or copy thereof.	
Name of conveying party(ies); ImaRx Pharmaceutical Corp.	Name and address of receiving party(les) Name: DuPont Contrast Imaging Inc. Internal Address: Legal Department	
Additional name(s) of conveying partyles) stached? Yes V No		
3. Nature of conveyance:		
· —		
Assignment Merger	Street Addrese: Route 206 & Provinceline Road	
Security Agreement Change of Name		
Other		
	City: Princeton State: NJ Zip: 08543-4000	
10/07/1999		
Execution Date:	Additional name(s) & address(es) attached? Yes 📝 No	
A. Patent Application No.(s) See attached Schedule B. Additional numbers a	B. Pstent No.(s) See attached Schedule A Rached? Yes No	
5. Name and address of party to whom correspondence		
concerning document should be mailed: Name: Denise Bierlein	7. Total fee (37 CFR 3.41)	
Internal Address: Legal Division:	Enclosed	
	Authorized to be charged to deposit account	
Street Address: Route 141 & Henry Clay Rd. Experimental Station, E353/133F	8. Deposit account number:	
	·	
City: Wilmington State: DE Zip: 19880-0353	•	
DO NOT U	SE THIS SPACE	
9, Signature:		
Denise Bierlein Name of Person Signing	inus Builles 02/08/02 Signature Date	

Itali decuments to be recorded with required cover shoot information to: Commissioner of Patents & Trademarks, Box Assignments Washington, O.C. 20239

PATENT

SCHEDULE A Granted Patents

BMS Docket#	UNGR Docket #	US Patent Number	Grant Date
BMS-0004	UNGR-0088	5.123.414	6/23/92
BMS-0007	UNGR-0301	ABANDONED	2/17/93
BMS-0008	UNGR-0320	5,334,381	8/2/94
BMS-0011	UNGR-0688	5,571,497	11/5/96
BMS-0089	UNGR-0048	5,228,446	7/20/93
BM5-0092	UNGR-0470	5,769,080	6/23/98
BMS-0375	UNGR-0974	5,846,517	1/30/97
BMS-0376	UNGR-1497	6,071,494	6/6/00
BMS-0003	UNGR-0019	5,088,499	2/18/92
BMS-0005	UNGR-0095	5,230,882	7/27/93
BMS-0006	UNGR-0279	5,352,435	10/4/94
BMS-0010	UNGR-0574	5,456,901	10/10/95
BMS-0012	UNGR-0728	6,001,335	12/14/99
BMS-0013	UNGR-1190	5,985,246	11/16/99
BMS-0045	UNGR-0046	5,205,290	4/27/93
BMS-0046	UNGR-0295	5,281,408	1/25/94
BMS-0047	UNGR-0346	5,456,900	10/10/95
BMS-0048	UNGR-0664	5,547,656	8/20/96
BMS-0049	UNGR-0665	5,527,521	6/18/96
BMS-0090	UNGR-0299	5,305,757	4/26/94
BMS-0091	UNGR-0319	5,348,016	9/20/94
BMS-0113	UNGR-0298	5,469,854	11/28/95
BMS-0114	UNGR-0686	5,715,824	2/10/98
BMS-0115	UNGR-0988	5,935,553	8/10/99
BMS-0139	UNGR-0348	5,542,935	8/6/96
BMS-0163	UNGR-0350	5,585,112	12/17/96
BMS-0164	UNGR-0685	5,853,752	12/29/98
BMS-0165	UNGR-1227	6,071,495	6/6/00
BMS-0191	UNGR-0480	5,773,024	6/30/98
BMS-0192	UNGR-0991	6,146,657	11/14/00
BMS-0221	UNGR-0570	5,705,187	1/6/98
BMS-0250	UNGR-0571	5,656,211	8/12/97
BMS-0251	UNGR-1035	6,039,557	3/21/00
BMS-0280	UNGR-0625	5,997,898	12/7/99
BMS-0331	UNGR-0725	6,033,645	3/7/00
BMS-0343	UNGR-0773	5,776,429	7/7/98
BMS-0344	UNGR-1286	6,033,646	3/7/00
BMS-0461	UNGR-1269	6,231,834	5/15/01
BMS-0533	UNGR-0569	5,830,430	11/3/98
BMS-0534	UNGR-0534	6,056,938	5/2/00

PATENT

SCHEDULE B Pending Patents

BMS Docket #	UNGR Docket#	US Serial Number	Filing Date
BMS-0009_	UNGR-0421	08/163,039	12/6/93
BMS-0366	UNGR-0882	08/712,173	9/11/96
BMS-0051	UNGR-1174	08/878,233	6/18/97
BMS-0093	UNGR-1267	09/000,522	12/30/97
BMS-0140	UNGR-0692	08/485,998	6/7/95
BMS-0166	UNGR-1340	09/118,329	7/17/98
BMS-0192	UNGR-0991	08/741,598	11/1/96
BMS-0193	UNGR-1283	09/052,075	3/31/98
BMS-0222	UNGR-1223	08/947,305	10/8/97
BMS-0306	UNGR-0944	08/660,032	6/6/96
BMS-0307	UNGR-1520	09/218,660	12/22/98
BMS-0332	UNGR-1556	09/290,324	4/12/99
BMS-0344	UNGR-1286	09/026,326	2/19/98
BMS-0399	UNGR-0990	60/031,903	11/25/96
BMS-0400	UNGR-0998	08/800,993	2/20/97
BMS-0437	UNGR-0992	08/915,103	8/20/97
BMS-0438	UNGR-1030	08/915,203	8/20/97
BMS-0439	UNGR-1032	08/796,798	2/6/97
BMS-0440	UNGR-1192	09/033,001	2/26/98
BMS-0441	UNGR-1172	08/929,847	9/15/97
BMS-0461	UNGR-1269	08/982,829	12/2/97
BMS-0462	UNGR-1285	60/073,913	2/6/98
BMS-0463	UNGR-1550	09/243,640	2/3/99
BMS-0510	UNGR-0510	09/573,264	5/18/00
BMS-0558	UNGR-1338	09/075,343	5/11/98
BMS-0596	UNGR-0596	09/901,934	7/10/01

RECORDED: 10/28/2009

PATENT